Market Intelligence, Clinical Progress, and High-Purity Reagents for Antioxidant and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SOD Mn drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOD Mn Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Recombinant expression optimized for native tetrameric conformation and manganese coordination. |
View SOD Mn Products |
| Gene Delivery | SOD Mn Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for intracellular ROS scavenging assays and mitochondrial localization studies. |
View SOD Mn Products |
| Benchmark Ab | Anti-SOD Mn Antibody Recombinant positive control for Western Blot, IHC, and intracellular localization validation. |
View SOD Mn Products |
| Validator | SOD Mn siRNA Set For specific knockdown verification in cellular oxidative stress models. |
View SOD Mn Products |
| Related Target A | SOD1 (Cu-Zn SOD) Cytosolic superoxide dismutase. Essential for selectivity profiling and off-target toxicity screening. |
View SOD1 Products |
| Related Target B | SOD3 (EC-SOD) Extracellular superoxide dismutase. Crucial for assessing tissue-specific targeting and systemic antioxidant network pharmacology. |
View SOD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic conformation verification | Manganese-loaded, native-state tetrameric recombinant proteins verified by size exclusion chromatography. |
| Isoform selectivity screening | Highly purified SOD1 and SOD3 homolog panels available for precise cross-reactivity and off-target evaluation. |
| Lack of Controls | Sequence-verified biosimilar-grade antibodies included to establish reliable assay baselines. |
| False Positives | Validated siRNA pools included for target-specific knockdown to confirm assay biological relevance. |
Live SOD Mn R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SOD Mn (Manganese Superoxide Dismutase, SOD2) is expanding beyond classic antioxidant supplementation into highly targeted oncology, radioprotection, and neurodegeneration pipelines. As a critical mitochondrial enzyme converting superoxide radicals into hydrogen peroxide, SOD Mn plays a dual role: its downregulation drives early oncogenesis, whereas its upregulation in advanced cancers promotes therapeutic resistance. Major pharmaceutical players are shifting focus from non-specific small-molecule mimetics to highly selective metalloporphyrins, enzyme-mimetic complexes, and gene therapy delivery systems targeting the mitochondrial matrix.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Mimetics | Galera Therapeutics, Clinigen | Radiotherapy-induced Oral Mucositis, Solid Tumors | Selectivity Assay (Need highly purified SOD1, SOD2, and SOD3 to confirm metal coordination specificity) |
| Gene Therapy / mRNA | Academic Consortia, Biotech Startups | Ischemia-Reperfusion Injury, Neurodegenerative Diseases | Transfection Validation (Need high-titer Lentivirus for stable cell line generation and expression benchmarks) |
| Recombinant Enzymes | Enzyme Therapeutics Developers | Inflammatory Diseases, Mitochondrial Disorders | Mitochondrial Internalization (Need sequence-verified, endotoxin-controlled recombinant proteins with intact targeting sequences) |